Roy M. Gulick, M.D., is the Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University. He serves as Principal Investigator for the NIH-funded AIDS Clinical Trials Group (ACTG) and HIV Prevention Trials Network (HPTN) clinical trials units. His research focuses on antiretroviral therapy for HIV treatment/prevention and pandemic response strategies for diseases like COVID-19. Education: B.A., Johns Hopkins University (1982) M.D., Columbia University College of Physicians and Surgeons (1986) M.P.H., Harvard School of Public Health (1993) Research Interests: Dr. Gulick specializes in clinical trials for HIV therapeutics, including novel antiretrovirals and long-acting formulations. His work integrates pharmacogenetics, adherence monitoring via mass spectrometry, and pandemic preparedness frameworks. He has led global studies on HIV-related metabolic changes, racial disparities in treatment outcomes, and co-infections like HIV/HCV. Scientific Awards: Elected to American Society for Clinical Investigation (ASCI) (2006) Lifetime Achievement Award, HIV Congress, Mumbai (2012) Mid-Career Investigator Award (K24), NIAID/NIH (2003-2013) Excellence in Teaching Award, Weill Cornell (2005) Companero Award, Latino Commission on AIDS (2002) Leadership & Collaborations: Dr. Gulick co-chairs the NIH COVID-19 Treatment Guidelines Panel and the U.S. DHHS HIV Clinical Practice Guidelines Panel. He collaborates with institutions like New York Presbyterian Hospital and has contributed to over 200 publications spanning HIV virology, pandemic response, and pharmacogenomics.










